In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Melissa Lattanzi, VP, Emerging Therapies, Cencora ...

Study findings indicated that psilocybin can reduce the symptoms of depression, with response and remission rates showing ...

With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued ...

The National Institute for Public Employee Healthcare Policy attributed the importance to the rising cost of health care.

Respondents said they were concerned about their own mental health or the mental health of another person at higher rates ...

It’s long past time for the industry to fully embrace the digital age. It’s fine to keep paper back-ups of data, but using ...

From Big Pharma to biotech—and a globe-spanning journey along the way—Yvonne Greenstreet, this year’s Healthcare ...

The new care center will offer primary care services to uninsured and underinsured patients in the Wilmington, North Carolina ...

The FDA first approved Ozempic, Novo Nordisk’s GLP-1 receptor agonist to improve glycemic control in adults with type 2 ...

For decades, one of the main priorities of the United States healthcare system has been to develop life-saving treatments for ...

As of the writing of this column (May 1), the XBI stood at $88.30, well off of its recent recovery high of $102+ on Feb. 27, ...

In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, talks about ensuring global access to LP ...